Nexalin Technology NXL 深 沪

Nexalin Technology Acquires Digital Health Platform PONM From GreenLight Ventures; Financial Terms Not Disclosed

Through the transaction, Nexalin has secured ownership of PONM and an exclusive license to the proprietary software features developed for the HALO™ program, including AI-integrated remote patient monitoring,

05-19 20:37

Nexalin To Begin Enrollment For Pivotal HALO Clarity Insomnia Trial In Q2 2026; Targeting FDA De Novo Pathway

Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced it has entered into agreements to

04-22 21:36

Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline results from ongoing Phase 2/3 trial.

04-13 17:27

Nexalin DIFS study shows reduced self-injury, depression symptoms in female adolescents

Nexalin DIFS study shows reduced self-injury, depression symptoms in female adolescents Nexalin disclosed peer-reviewed BMC Psychiatry results from a preliminary pilot study of its non-invasive DIFS brain-stimulation approach in female adolescents with non-suicidal self-injury. Results have already

04-09 19:47

EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device

Nexalin study shows reduced self-injury and depression in adolescents using DIFS, with brain connectivity changes and early safety data.

04-09 19:33

Nexalin Technology Q4 EPS $(0.13) Misses $(0.12) Estimate, Sales $171.895K Beat $80.000K Estimate

Nexalin Technology (NASDAQ:NXL) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 53.57 percent increase over losses of $(0.28) per share

03-26 06:09

Nexalin Advances Pivotal HALO Clarity Trial for Insomnia

An update from Nexalin Technology, Inc. ( ($NXL) ) is now available. On Februar...

02-26 03:58

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s disease. Nexalin Technology, Inc. commended recent bipartisan Congressional initiatives expanding federal focus on deep brain neurostimulation and related neuromodulation research within the U.S. Department of Veterans Affairs (VA) and the National Institutes of Health (NIH). Nexalin’s DIFS™ techno...

02-23 13:18

Nexalin Technology Validates DIFS™ Neurostimulation with New Clinical Research Across Multiple Brain Disorders

Nexalin Technology Validates DIFS™ Neurostimulation with New Clinical Research Across Multiple Brain Disorders Nexalin Technology Inc. has highlighted new peer-reviewed clinical research validating its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology across multiple neurologica

02-02 21:45

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

02-02 13:45